Use of Cystatin C to Assess Kidney Function
Cystatin C PENIA Assay Shift (19%)
August 2011
Therefore, we pulled some older samples that had been run on the PENIA in 2000 and stored at -70 degrees since. Surprisingly, they were 19% lower when rerun on the PENIA in 2010. Therefore, there appears to have been assay drift in the commonly used PENIA platform between 2000 and 2010. Importantly, recent publications have reported a similar shift in values using the same nephelometric assay for cystatin C in other laboratories. The standardization of the new turbidometric assay to an international cystatin C reference material is a major advantage, and should prevent similar drift in values over time.
Cystatin C PENIA Assay Shift (19%) |
Jump to section:
- Introduction
- A Case
- Questions
- What do the kidneys do?
- Why Measure Renal Function?
- How Is Chronic Kidney Disease (CKD) Defined?
- Stages of Chronic Kidney Disease
- Laboratory Assessment of Kidney Function: What Can We Measure?
- Creatinine as a Marker of GFR
- Creatinine as a Marker of GFR: It Works But...
- How Can We Turn the Serum Creatinine Into a Better Estimate of GFR?
- Revised eGFR Equation (ID-MS version)
- eGFR Equation Works, But it's Not Perfect
- What About Cystatin C?
- Mayo Renal Laboratory Cystatin C By Particle Enhanced Turbidometric Immunoassay (PETIA)
- Comparison To Current Nephelometric Assay (PENIA) Reveals 23% Bias
- Cystatin C PENIA Assay Shift (19%)
- Cystatin C eGFR Using Published Equation* Performs Well3
- Cystatin C Equations Categorize Patients Slightly Better Than MDRD eGFR
- Cystatin C Reference Range
- PETIA Cystatin C Reference Range
- Cystatin C: Useful To Confirm Those At Risk Of CKD Progression And Its Complications (REGARDS)4
- Cystatin C: CKD Progression and Complications (MESA and CHS)5
- Cystatin C in the Acute Hospitalized Setting6
- Back to Our Patient
- Potential Interventions
- Conclusions
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document